Piper Sandler: Transformative License Transaction, Raised Aclaris (ACRS.US) target to $13
Tuesday, Nov 19, 2024 1:20 am ET
1min read Aclaris Therapeutics (ACRS.US) shares rose 53% to $3.14 on Monday after the biopharmaceutical company announced it had secured exclusive rights to two immunotherapy candidates from Biosion, prompting Piper Sandler to upgrade the company's rating.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.